drugset / Trial / NCT02644486
A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy
RandomizedParallel-groupOpen-labelTreatment
Summary
To observe the decreased levels of low-density lipoprotein from baseline in patients with obesity-related glomerulopathy (ORG) after 12 weeks of Sevelamer Carbonate treatment.
Timeline
- Start
- 2016-01
- Primary completion
- 2018-02
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sevelamer | Other / unclassified | 2.4 g | — |
| Subject | sevelamer | Other / unclassified | 4.8 g | — |
| Comparator | Irbesartan | Small molecule | 300 mg | — |